HIV, pneu­mo­coc­cal — and what? Mer­ck­'s un­ex­pect­ed pipeline high­light ex­cites a lit­tle biotech

In an R&D up­date dom­i­nat­ed by on­col­o­gy — most­ly Keytru­da, fol­lowed by Lyn­parza and Lenvi­ma — Mer­ck chose to high­light a pro­gram in sen­so­ry pathol­o­gy, an HIV drug, and a group of pneu­mo­coc­cal vac­cines. And that has made at least one biotech very hap­py.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER